ArticleThe British journal of general practice : the journal of the Royal College of General Practitioners2023
Polypharmacy and antidepressant acceptability in comorbid depression and type 2 diabetes: a cohort study using UK primary care data.
Article in The British journal of general practice : the journal of the Royal College of General Practitioners, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Bridging clinical needs and economic barriers: a national survey of antidepressant prescribing across 25 hospitals in Thailand.International journal of mental health systems · 2026Article
- Drug-Induced Orthostatic Hypotension in UK Primary Care: A Self-Controlled Case Series Study.Clinical epidemiology · 2026Article
- Beyond the medical file: A scoping review on patients' perspectives on depression treatment in primary care.PloS one · 2025Article
- The Interconnected Complexity of Diabetes and Depression.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Study on the changes and influencing factors of depression in Chinese women with cancer: an analysis based on CHARLS panel data.Frontiers in public health · 2024Article
- Real-world outcomes of concomitant antidepressant and statin use in primary care patients with depression: a population-based cohort study.BMC medicine · 2023Article
- The effectiveness of virtual reality to improve depression: A systematic evidence map.Digital healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolypharmacy may increase the risk of drug interactions, side effects, and poor adherence; however, the impact of polypharmacy on antidepressant acceptability in individuals with type 2 diabetes (T2DM) is unknown.
aimTo investigate the association between number of prescribed medications and early antidepressant discontinuation in adults with T2DM. DESIGN AND
settingCohort study using UK primary care data from the Clinical Practice Research Datalink between 1 January 2000 and 31 December 2018.
methodCox regression with penalised B-splines was used to describe the association between the number of concurrently prescribed medications at the time of starting antidepressant treatment and each of the outcomes.
resultsA total of 73 808 individuals with comorbid depression and T2DM starting antidepressant treatment for the first time were identified. A median of 7 concurrent medications were prescribed. Within 32 weeks, 44.26% (
conclusionEarly discontinuation of antidepressants is common in adults with T2DM; however, individuals with higher levels of concurrent polypharmacy may be more adherent to treatment. These are likely to represent individuals with worse physical or mental health. Individuals with lower levels of concurrent polypharmacy may benefit from adherence support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.